SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the completion of the SAD portion of the Phase 1 study of its oral main viral ...
Corbus Pharmaceuticals reports no neuropsychiatric events in CRB-913 trial, advancing to multiple ascending dose phase. Study completion projected for Q3 2025. Corbus Pharmaceuticals Holdings Inc. has ...
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results